Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04868981
Other study ID # GST-HG141-21-01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 31, 2021
Est. completion date March 14, 2022

Study information

Verified date April 2021
Source Fujian Cosunter Pharmaceutical Co. Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To Evaluate the Tolerability, Pharmacodynamics and Pharmacokinetics of GST-HG141 Tablets in Multiple-center, Randomized, Double-blind, Placebo-controlled Multiple-dose, Multiple-administration Study in Patients With Chronic Hepatitis B (CHB)


Description:

This study includes 3 cohorts of 25 mg BID, 50 mg BID and 100 mg BID. 30 patients with chronic hepatitis B will be enrolled in this study and each cohort will enroll 10 patients (GST-HG141 tablets : PBO=8:2). All enrolled patients will be given research drugs twice a day for 28 days (D28 was administered only once in the morning). And each cohort requires at least 4 subjects with elevated ALT. Tolerability, pharmacodynamics and pharmacokinetics will be evaluated according to the protocol.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date March 14, 2022
Est. primary completion date February 23, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Sign the informed consent before the study and fully understand the content and process of the study as well as the possible adverse drug reactions; 2. Be able to complete the study in accordance with protocol requirements; 3. Subjects (including partners) are willing to take effective contraceptive measures from completion of screening to 6 months after the last Administration; 4. Ages ranged from 18 to 70 years old (including 18 and 70 years old); 5. Male subjects weighing no less than 45 kg, and female subjects weighing no less than 40 kg. [Body mass index (BMI) = body weight (kg) / height 2 (m^2)], body mass index is in the range of 18 ~ 32 kg / m^2 (including critical value); 6. Patients with HBsAg-positive for at least 6 months (based on outpatient/inpatient medical records or laboratory report; or with IgM HBcAb-negative and HBsAg-positive when screening; 7. Patients without interferon/nucleoside analogue treatment when screening, or interferon treatment was stopped more than 1 year ago, and nucleoside analogue treatment was stopped more than 6 months ago. 8. For HBeAg-positive patients, HBV DNA = 2×10^5 IU/mL; For HBeAg-negative patients, HBV DNA = 2×10^4 IU/mL; 9. Patients with Serum ALT less than 5×ULN when screening. Exclusion Criteria: 1. Patients with suspected allergy to any component of the study drug or allergic constitution (multiple drug and food allergy); 2. Patients who had major trauma or Large surgical operation within 3 months before screening or are planning to take surgical treatment during the study ; 3. Patients who had blood donation or massive blood loss (=400 mL), or had a blood transfusion within 3 months before screening; or had blood donation or massive blood loss (=200 mL) within 1 months before screening; 4. Patients with smoking more than 5 cigarettes per day within 3 months before the study or heavy drinking within 4 weeks before screening (drinking more than 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); 5. Patients who had used immunosuppressants, immunomodulators (thymosin) and cytotoxic drugs within 6 months before dosing, or had received live attenuated vaccine within 1 month before screening; 6. Patients who used immunosuppressants, immunomodulators (thymosin) and cytotoxic drugs within 6 months before dosing, or who had received live attenuated vaccine within 1 month before screening; 7. Patients with clinically significant acute or chronic liver disease caused by non HBV infection (fatty liver disease is ruled out or recruited by researcher); 8. Patients with history of liver cirrhosis or progressive liver fibrosis (e.g., liver histopathology reported liver cirrhosis or endoscopy indicated esophageal and gastric varices); 9. Patients with confirmed or suspected decompensated hepatitis B cirrhosis including but not limited to: hepatic encephalopathy, hepatorenal syndrome, esophageal and gastric variceal bleeding, splenomegaly, ascites, primary liver cancer, etc. ; 10. Patients with history of other malignancies or complicating with other malignant tumors; 11. Patients complicating with severe circulatory, digestive, respiratory, urinary, blood, metabolism, immune, nervous and other systemic; 12. Patients with acute infection within 2 weeks before screening; 13. Patients who had participated in clinical trials of drugs or medical devices within 1 month before screening; 14. Patients who could not ban smoking, drinking, caffeinated food or drinks within 2 days before administration and during the study , and patients who have special dietary requirements and can not follow the unified diet; 15. Laboratory examination: platelet count<90×10^9/L; leukocyte count<3.0×10^9/L; neutrophil absolute value<1.3×10^9/L; serum total bilirubin>2×ULN; albumin<30 g/L; creatinine clearance rate=60ml/min (calculated by MDRD formula); international standardization ratio value of prothrombin time (INR) >1.5; 16. Patients with Alpha fetoprotein (AFP) more than 50 UG / L or imaging findings of malignant liver lesions; 17. Patients with HCAb-positive , AIDS Ag/Ab-positive, or positive syphilis spirochemical Ab simultaneously RPR test-positive; 18. For patients with normal ALT or less than 2×ULN, LSM=12.4 kPa; or for patients with ALT=2×ULN, LSM=17.0 kPa; 19. Patients with positive urine drug screening (morphine, marijuana) or alcohol breath test; 20. Patients with positive urine drug screening (morphine, marijuana) or alcohol breath test; 21. Patients with other factors that are not suitable to participate in this study in researcher's thought.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
GST-HG141 tablets
Administrate GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses
Matching Placebos for GST-HG141 tablets
Administrate the placebos for GST-HG141 tablets orally in fed state twice daily at 25 mg or 50mg or 100 mg doses

Locations

Country Name City State
China The first hospital of Jilin University Changchun Jilin

Sponsors (1)

Lead Sponsor Collaborator
Fujian Cosunter Pharmaceutical Co. Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with chronic HBV infection with treatment-related adverse events and laboratory abnormalities. Symptoms and physical examination, clinical laboratory examination, vital signs,12 lead ECG and adrenal ultrasounds were collected and assessed by CTCAE v5.0. Up to 33 days
Primary Cmax of GST-HG141 Plasma samples were collected at different points for pharmacokinetic analysis Measured on -0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12hours on Day1; -0.5 hours on Day 8, Day 15, Day22 and Day 27 for trough concentration; -0.5, 0.5 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours on Day 28.
Primary AUC of GST-HG141 Plasma samples were collected at different points for pharmacokinetic analysis Measured on -0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12hours on Day1; -0.5 hours on Day 8, Day 15, Day22 and Day 27 for trough concentration; -0.5, 0.5 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours on Day 28.
Primary t1/2 of GST-HG141 Plasma samples were collected at different points for pharmacokinetic analysis Measured on -0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12hours on Day1; -0.5 hours on Day 8, Day 15, Day22 and Day 27 for trough concentration; -0.5, 0.5 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours on Day 28.
Primary Cl/F of GST-HG141 Plasma samples were collected at different points for pharmacokinetic analysis Measured on -0.5, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12hours on Day1; -0.5 hours on Day 8, Day 15, Day22 and Day 27 for trough concentration; -0.5, 0.5 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours on Day 28.
Secondary The value of serum HBV DNA decreased from baseline Plasma samples were collected at different points for pharmacodynamics analysis Plasma samples were collected before administation on the morning of day 1 and day 15 and at any time on day 29 and day 33
Secondary The value of serum HBV pgRNA decreased from baseline Plasma samples were collected at different points for pharmacodynamics analysis Plasma samples were collected before administation on the morning of day 1 and day 15 and at any time on day 29 and day 33
Secondary The value of serum HBsAg decreased from baseline Plasma samples were collected at different points for pharmacodynamics analysis Plasma samples were collected before administation on the morning of day 1 and day 15 and at any time on day 29 and day 33
Secondary The value of serum HBeAg decreased from baseline Plasma samples were collected at different points for pharmacodynamics analysis Plasma samples were collected before administation on the morning of day 1 and day 15 and at any time on day 29 and day 33
See also
  Status Clinical Trial Phase
Completed NCT01182311 - Duration of Long-term Immunity After Hepatitis B Virus Immunization
Completed NCT04971928 - Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment Phase 1
Completed NCT03285620 - A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants Phase 1
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05404919 - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates Phase 2
Completed NCT02153320 - Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers Phase 1
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Completed NCT03567382 - Arresting Vertical Transmission of Hepatitis B Virus Phase 4
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Not yet recruiting NCT03604016 - Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Completed NCT02540538 - Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders Phase 1
Terminated NCT02604199 - A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection Phase 2
Completed NCT02169674 - Hepatitis B Booster Study in Adolescence Phase 4
Completed NCT02421666 - A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV N/A
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01368497 - Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection Phase 3
Completed NCT01732354 - Study for Consolidation Period of Chronic Hepatitis B
Recruiting NCT01462981 - Cohort of Hepatitis B Research of Amsterdam N/A